Sign In
Buy VERU
$2.77
+0.440 (+18.88%)
At Close: Aug 10, 2026
VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
07:00am, Monday, 14'th Dec 2020
-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer
Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call Transcript
01:40pm, Wednesday, 09'th Dec 2020
Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call Transcript
-- Transformation to P remium O ncology B iopharmaceutical C ompany with L ate - S tage Clinical Drug P ipeline F ocused on P rostate and B reast C ancer is C omplete -- -- Company Poised to Initiate
Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results
06:30am, Wednesday, 09'th Dec 2020
—FY20 Full-Year Net Revenue s and Gross Profit Achieve Historical Highs o f $4 3 M illion and $ 31 M illion , Respectively—
Preview: Veru's Earnings
10:05am, Tuesday, 08'th Dec 2020
Veru (NASDAQ:VERU) releases its next round of earnings this Wednesday, December 09. Here is Benzinga's essential guide to Veru's Q4 earnings report.
Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th
08:30am, Monday, 23'rd Nov 2020
MIAMI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, t
